From the Department of Anesthesiology.
Department of Epidemiology.
Anesth Analg. 2021 Mar 1;132(3):743-751. doi: 10.1213/ANE.0000000000004837.
Over 6 million esophagogastroduodenoscopy (EGD) procedures are performed in the United States each year. Patients having anesthesia for advanced EGD procedures, such as interventional procedures, are at high risk for hypoxemia.
Our primary study aim was to evaluate whether high-flow nasal cannula (HFNC) oxygen reduces the incidence of hypoxemia during anesthesia for advanced EGD. Secondarily, we studied whether HFNC oxygen reduces hypercarbia or hypotension. After obtaining written informed consent, adults having anesthesia for advanced EGD, expected to last longer than 15 minutes, were randomly assigned to receive HFNC oxygen or standard nasal cannula (SNC) oxygen. The primary outcome was occurrence of one or more hypoxemia events during anesthesia, defined by arterial oxygen saturation <92% for at least 15 consecutive seconds. Secondary outcomes were occurrence of one or more hypercarbia or hypotension events. A hypercarbia event was defined by a transcutaneous CO2 measurement 20 mm Hg or more above baseline, and a hypotension event was defined by a mean arterial blood pressure measurement 25% or more below baseline.
Two hundred seventy-one adult patients were enrolled and randomized, and 262 patients completed study procedures. Eight randomized patients did not complete study procedures due to changes in their anesthesia or endoscopy plan. One patient was excluded from analysis because their procedure was aborted after 1 minute. Patients who received HFNC oxygen (N = 132) had a significantly lower incidence of hypoxemia than those who received SNC oxygen (N = 130; 21.2% vs 33.1%; hazard ratio [HR] = 0.59 [95% confidence interval {CI}, 0.36-0.95]; P = .03). There was no difference in the incidence of hypercarbia or hypotension between the groups. The HR for hypercarbia with HFNC oxygen was 1.29 (95% CI, 0.89-1.88; P = .17), and the HR for hypotension was 1.25 (95% CI, 0.86-1.82; P = .25).
HFNC oxygen reduces the incidence of hypoxemia during anesthesia for advanced EGD and may offer an opportunity to enhance patient safety during these procedures.
在美国,每年进行超过 600 万次食管胃十二指肠镜检查(EGD)。对于接受高级 EGD 程序(如介入程序)麻醉的患者,低氧血症的风险很高。
我们的主要研究目的是评估高流量鼻导管(HFNC)氧是否会降低高级 EGD 麻醉期间低氧血症的发生率。其次,我们研究了 HFNC 氧是否会降低高碳酸血症或低血压。在获得书面知情同意后,预计持续时间超过 15 分钟的接受高级 EGD 麻醉的成年人被随机分配接受 HFNC 氧或标准鼻导管(SNC)氧。主要结局是麻醉期间发生一次或多次低氧血症事件,定义为动脉血氧饱和度<92%至少 15 秒。次要结局是发生一次或多次高碳酸血症或低血压事件。高碳酸血症事件定义为经皮二氧化碳测量值比基线高 20mmHg 或以上,低血压事件定义为平均动脉血压测量值比基线低 25%或以上。
共有 271 名成年患者入组并随机分组,262 名患者完成了研究程序。由于麻醉或内镜计划的改变,8 名随机患者未完成研究程序。由于 1 分钟后手术中止,1 名患者被排除在分析之外。接受 HFNC 氧(N=132)的患者发生低氧血症的发生率明显低于接受 SNC 氧(N=130)的患者(21.2% vs. 33.1%;危险比[HR] = 0.59[95%置信区间{CI},0.36-0.95];P=0.03)。两组之间高碳酸血症或低血压的发生率无差异。HFNC 氧治疗高碳酸血症的 HR 为 1.29(95%CI,0.89-1.88;P=0.17),低血压的 HR 为 1.25(95%CI,0.86-1.82;P=0.25)。
HFNC 氧可降低高级 EGD 麻醉期间低氧血症的发生率,并可能为这些程序中提高患者安全性提供机会。